The goal of this course is to enhance the knowledge, competence, and skills of nurse practitioners (NPs), primary care physicians (PCPs), and physician assistants (PAs) in initiating and intensifying basal insulin therapies according to clinical practice guidelines to achieve timely and sustained glycemic control for individuals with T2DM. This program is designed for healthcare providers who have basic knowledge of diabetes care and experience in managing patients with T2DM but who may not be comfortable prescribing or intensifying basal insulin therapy. 

Faculty

Debbie Hinnen, APN, BC-ADM, CDCES, FAAN 
Advanced Practice Nurse and Certified Diabetes Care and Education Specialist 
University of Colorado Health 
Colorado Springs, CO 
 
Rodolfo J. Galindo, MD, FACE 
Associate Professor of Medicine 
University of Miami Miller School of Medicine 
Director, Comprehensive Diabetes Center  
Lennar Medical Center, UMiami Health System 
Director, Diabetes Management 
Jackson Memorial Health System 


Price: FREE for all

Upon successful completion of the program, participants should be better able to:   

• Review the latest evidence-based guidelines on implementing appropriate initiation of basal insulin to achieve individual glycemic goals 
• Identify patients with T2DM who will benefit from insulin therapy 
• Evaluate therapies that reach timely, sustained glycemic control targets in various patients 
• Develop personalized insulin treatment plans for patients with T2DM by comparing emerging, new, and evolving insulin therapies and therapy combinations 

Primary care team members, including nurse practitioners, physician assistants, and primary care physicians working with patients with diabetes. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AACE and AANP. AACE is accredited by the ACCME to provide continuing medical education for physicians 

Physicians
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.  

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.

Nurses
This activity is approved for 1.75 contact hours of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID # 23116452. This activity was planned in accordance with AANP Accreditation Standards and Policies. 

This activity is supported by an independent medical education grant from Novo Nordisk. 

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. 

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  

All of the relevant financial relationships listed for these individuals have been mitigated.  

• Jessica Martin, PhD, ELS - No relationships to disclose 
• Rachel L. Watkins, PharmD, MPH - No relationships to disclose 
• Michele L. McKay, MSN, APRN, FNP-C, CHCP - No relationships to disclose 
• Amy Ogunsunlade - No relationships to disclose 
• Diane Alberson, MEd, CAE - No relationships to disclose 

Faculty

• Debbie Hinnen - Speaker’s Bureau/Consultant/Advisory Board—Diabetes: Eli Lilly, BI, Novo Nordisk 
  • Speaker’s Bureau/Advisor—Diabetes: Intuity 
• Rodolfo Galindo - Advisory/Consultant/Honoraria fees—Diabetes: Novo Nordisk, Eli Lilly, Sanofi, Bayer, Abbott, Dexcom 
  • Research Studies—Diabetes: Novo Nordisk, Eli Lilly, Dexcom 

https://my.aace.com/NC__Product?id=a1B5a00000qWFfTEAW

FREE

2

1

ENDO, PCP, NP, PA, EDU

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.